An observational study in Percutaneous Coronary Intervention and Multivessel Coronary Artery Disease, sponsored by Genoss Co., Ltd.. Enrolling by invitation at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-10-06.
Sponsored by Genoss Co., Ltd. · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Coronary Artery Disease by Genoss Co., Ltd. — 6 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Genoss Co., Ltd..
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 8th registered.
4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.
Browse Coronary Artery Disease studies →6 of the 10 studies in Coronary Artery Disease by Genoss Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 20+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
Genoss Co., Ltd. · Sites in Korea, Republic of
Ages 19+
By country, each count listing its studies:
Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.
This study: 19 Years and older · all sexes.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 1,000 is above the median of 323 across 1,690 observational studies indexed under Coronary Artery Disease.
Median enrollment 214 across the 4 interventional studies, 1,000 across the 6 observational. Of the 4 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Genoss Co., Ltd. is the lead sponsor of 18 studies on the registry; 11 are open to participants now.
1 of the studies in Coronary Artery Disease by Genoss Co., Ltd. that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06066450Genoss Co., Ltd.Efficacy of OSFIT Drug-Eluting Stent in Coronary Ostial Artery Stenosis | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 10 studies in Coronary Artery Disease by Genoss Co., Ltd., from their registry updates:
This tab as a report to print or save as PDF → With an account.
The investigators intend to establish a multicenter prospective observational study by enrolling and tracking patients with multivessel coronary artery disease (MVCAD) using Genoss DES, a device manufactured with pure domestic technology. The study aims to evaluate the efficacy and safety of Genoss DES in MVCAD patients.
This study is a sponsor-driven clinical trial (SIT) that aims to enroll patients who have undergone treatment for multivessel coronary artery disease using Genoss stents. The study involves collecting data on the clinical and surgical processes of patients and tracking the occurrence of clinical events.
This prospective, multicenter observational study registers patients with acute coronary artery disease who have been treated with GENOSS stents at a total of 8 institutions.
As it is an observational study, the number of subjects is not separately calculated, but the plan is to recruit a total of 1,000 participants during the study registration period.
Patients with multivessel coronary artery disease (MVCAD) who underwent percutaneous coronary intervention using GENOSS® DES
\<Inclusion Criteria>
(However, in the case of foreigners, only those who can speak Korean fluently and understand Korean documents such as the consent form are included.)
\<Exclusion Criteria>
Subject
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with multivessel coronary artery disease (MVCAD) who underwent percutaneous coronary intervention using GENOSS® DES
Device: GENOSS® DES Sirolimus Eluting Coronary Stent System
The GENOSS® DES is L-605 cobalt chromium (CoCr) platform with a strut thickness of 70µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
Target Lesion Failure (TLF)
The composite end point of cardiac death, TV-MI (target vessel-MI), and TLR (target lesion revascularization)
Time frame: at 12 months after the procedure
Major adverse cardiac events (MACE)
The composite end point of death, myocardial infarction, target lesion revascularization
Time frame: at 12 months after the procedure
Cardiac death
Time frame: at 12 months after the procedure
Non-cardiac death
Time frame: at 12 months after the procedure
TV-MI (target vessel-myocardial infarction)
Time frame: at 12 months after the procedure
Non-target vessel myocardial infarction
Time frame: at 12 months after the procedure
ID-TVR (ischemia-driven target vessel revascularization)
Time frame: at 12 months after the procedure
Non-ischemia driven target vessel revascularization
Time frame: at 12 months after the procedure
Incidence rate of acute stent thrombosis within 24 hours, subacute stent thrombosis within 30 days, and late stent thrombosis at 1 year
Acute (within 24 hours), subacute (within 30 days), late (within 1 year)
Time frame: within 24 hours, 30 days, 1 year
Device success
The clinical device is successfully delivered to the target lesion, inflated normally, and recovered intact.
Time frame: during the procedure
Procedure success
When the final residual lesion stenosis is less than 50% using any surgical method, and there is no post-procedural death, myocardial infarction, or revascularization during the hospitalization period.
Time frame: during the hospitalization period (up to 3 days)
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2023 (actual). Primary completion is estimated for Feb 2028, 51 months after the start.
Of 125 industry-sponsored observational studies under Coronary Artery Disease, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 51 months is above that.
Counting every sponsor, half of 762 studies reached it within 41 months; a quarter within 21 and three quarters within 87.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Genoss Co., Ltd.